The HDAC Inhibitor LBH589 Induces ERK-Dependent Prometaphase Arrest in Prostate Cancer via HDAC6 Inactivation and Down-Regulation

Histone deacetylase inhibitors (HDACIs) have potent anti-cancer activity in a variety of cancer models. Understanding the molecular mechanisms involved in the therapeutic responsiveness of HDACI is needed before its clinical application. This study aimed to determine if a potent HDACI, LBH589 (Panobinostat), had differential therapeutic responsiveness towards LNCaP and PC-3 prostate cancer (PCa) cells. The former showed prometaphase arrest with subsequent apoptosis upon LBH589 treatment, while the latter was less sensitive and had late G2 arrest. The LBH589 treatment down-regulated HDAC6 and sustained ERK activation, and contributed to prometaphase arrest. Mechanistically, LBH589 inhibited HDAC6 activity, caused its dissociation from protein phosphatase PP1α, and increased 14-3-3ζ acetylation. Acetylated 14-3-3ζ released its mask effect on serine 259 of c-Raf and serine 216 of Cdc25C subsequent to de-phosphorylation by PP1α, which contributed to ERK activation. Enhanced ERK activity by LBH589 further down-regulated HDAC6 protein levels and sustained ERK activation by free-forward regulation. The sustained Cdc25C and ERK activation resulted in early M-phase (prometaphase) arrest and subsequent apoptosis in the most sensitive LNCaP cells but not in PC-3 cells. This study provides pre-clinical evidence that HDAC6 may serve as a sensitive therapeutic target in the treatment of prostate cancer with HDACI LBH589 for clinical translation. This study also posits a novel mechanism of HDAC6 participation in regulating the c-Raf-PP1-ERK signaling pathway and contributing to M phase cell-cycle transition.

[1]  J. Chambard,et al.  ERK and cell death: Mechanisms of ERK‐induced cell death – apoptosis, autophagy and senescence , 2010, The FEBS journal.

[2]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[3]  Matthew H. Brush,et al.  Deactylase Inhibitors Disrupt Cellular Complexes Containing Protein Phosphatases and Deacetylases* , 2004, Journal of Biological Chemistry.

[4]  S. Shenolikar,et al.  PP1 control of M phase entry exerted through 14‐3‐3‐regulated Cdc25 dephosphorylation , 2003, The EMBO journal.

[5]  Yu-Chih Yang,et al.  Herbal Extract of Wedelia chinensis Attenuates Androgen Receptor Activity and Orthotopic Growth of Prostate Cancer in Nude Mice , 2009, Clinical Cancer Research.

[6]  J. Vance,et al.  The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress , 2003, Cell.

[7]  Kun-Liang Guan,et al.  Mechanisms of regulating the Raf kinase family. , 2003, Cellular signalling.

[8]  Ping-Hui Tseng,et al.  Histone Acetylation-independent Effect of Histone Deacetylase Inhibitors on Akt through the Reshuffling of Protein Phosphatase 1 Complexes* , 2005, Journal of Biological Chemistry.

[9]  James Bradner,et al.  Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 , 2005, Journal of Biological Chemistry.

[10]  Sheng-Tang Wu,et al.  Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer Cells , 2009, Clinical Cancer Research.

[11]  P. Atadja,et al.  Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. , 2008, Blood.

[12]  T. Haystead,et al.  A role for PP1 in the Cdc2/Cyclin B-mediated positive feedback activation of Cdc25. , 2006, Molecular biology of the cell.

[13]  P. Marks,et al.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Kirschner,et al.  Regulation of Cdc25C by ERK-MAP Kinases during the G2/M Transition , 2007, Cell.

[15]  Jung-Hyun Park,et al.  Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase , 2007, Journal of Molecular Medicine.

[16]  P. Atadja.  Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. , 2009, Cancer letters.

[17]  P. Matthias,et al.  HDAC‐6 interacts with and deacetylates tubulin and microtubules in vivo , 2003, The EMBO journal.

[18]  W. Kolch,et al.  Raf-1-associated Protein Phosphatase 2A as a Positive Regulator of Kinase Activation* , 2000, The Journal of Biological Chemistry.

[19]  D. Fairlie,et al.  Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. , 2000, Molecular biology of the cell.

[20]  J. Hancock,et al.  Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions , 2001, Oncogene.

[21]  D. Lee,et al.  Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. , 2008, Biochemical pharmacology.

[22]  J. Shen,et al.  Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. , 2008, Cancer research.

[23]  S. Vijayaraghavan,et al.  Identification of testis 14–3-3 binding proteins by tandem affinity purification , 2011, Spermatogenesis.

[24]  Ting-Fang Wang,et al.  Genetic Requirements and Meiotic Function of Phosphorylation of the Yeast Axial Element Protein Red , 2010, Molecular and Cellular Biology.

[25]  S. Pelech,et al.  Positive Regulation of Raf1-MEK1/2-ERK1/2 Signaling by Protein Serine/Threonine Phosphatase 2A Holoenzymes* , 2005, Journal of Biological Chemistry.

[26]  W. Kolch.  Coordinating ERK/MAPK signalling through scaffolds and inhibitors , 2005, Nature Reviews Molecular Cell Biology.

[27]  B. Garcia,et al.  A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. , 2006, Genes & development.

[28]  F. Sánchez‐Madrid,et al.  HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. , 2008, Trends in cell biology.

[29]  D. Morrison,et al.  Unlocking the code of 14-3-3 , 2004, Journal of Cell Science.

[30]  Delong Liu,et al.  Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents , 2010, Journal of hematology & oncology.

[31]  Walter Kolch,et al.  Untying the regulation of the Raf-1 kinase. , 2002, Archives of biochemistry and biophysics.

[32]  A. Nairn,et al.  PP1-mediated dephosphorylation of phosphoproteins at mitotic exit is controlled by inhibitor-1 and PP1 phosphorylation , 2009, Nature Cell Biology.

[33]  Walter Kolch,et al.  Phosphatase and Feedback Regulation of Raf-1 Signaling , 2007, Cell cycle.

[34]  Su-Jae Lee,et al.  Oxidative stress-induced apoptosis is mediated by ERK1/2 phosphorylation. , 2003, Experimental cell research.

[35]  J. Lasky,et al.  Requirement of HDAC6 for Transforming Growth Factor-β1-induced Epithelial-Mesenchymal Transition* , 2008, Journal of Biological Chemistry.

[36]  K. Sakamoto,et al.  The Role of HDAC6 in Cancer , 2010, Journal of biomedicine & biotechnology.

[37]  K. Bhalla,et al.  HDAC inhibitors and chaperone function. , 2012, Advances in cancer research.